Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin)...


The manuscript, which summarizes the five-year, end-of-study results, highlights that patients who attained a complete response achieved long-term disease control. The manuscript is available online today and will be included in a future print edition of Blood .



from Biotech News